MondegarAI
Opaleye Management Inc.

Q3 2025 · 13F-HR

Opaleye Management Inc.holdings as filed

Filed 2025-11-14 · accession 0001493152-25-023429

$707.3M
Reported value
43
Positions
2025-09-30
Period end
View analyzed profile →PRO

The Brief · Opaleye Management Inc. · Q3 2025

AI · grounded in 13F

Opaleye Management Inc. established a new position in Harrow Health Inc. HROW valued at $188.1M. The fund also initiated new stakes in Eton Pharmaceuticals Inc. ETON for $62.1M and Liquidia Corporation LQDA for $59.5M. Other new additions include Rhythm Pharmaceuticals Inc. RYTM and Immunome Inc. IMNM.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
415858109HROWHARROW HEALTH INC$188.1M26.6%3,905,000CommonSOLE
29772L108ETONETON PHARMACEUTICALS INC$62.1M8.79%2,860,000CommonSOLE
53635D202LQDALIQUIDIA CORPORATION$59.5M8.41%2,615,000CommonSOLE
76243J105RYTMRHYTHM PHARMACEUTICALS INC$46.6M6.59%461,700CommonSOLE
45257U108IMNMIMMUNOME INC$37.3M5.27%3,185,000CommonSOLE
80303D305SNWVSANUWAVE HEALTH INC$36.7M5.19%980,000CommonSOLE
192005106CDXSCODEXIS INC$31.2M4.41%12,795,000CommonSOLE
88322Q108TGTXTG THERAPEUTICS INC$19.3M2.73%535,000CommonSOLE
67576A100OCULOCULAR THERAPEUTIX INC$18.6M2.64%1,595,000CommonSOLE
156944100CGONCG ONCOLOGY INC$16.5M2.33%410,000CommonSOLE
86150R107STOKSTOKE THERAPEUTICS INC$16.0M2.27%682,017CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$14.4M2.04%363,257CommonSOLE
G01767105ALKSALKERMES PLC$13.5M1.91%450,000CommonSOLE
254604101IRONDISC MEDICINE INC$12.8M1.81%193,773CommonSOLE
803607100SRPTSAREPTA THERAPEUTICS INC$11.3M1.59%585,000CommonSOLE
517125100LRMRLARIMAR THERAPEUTICS INC$10.6M1.49%3,720,867CommonSOLE
98419J206XOMAXOMA CORP DEL$9.8M1.39%255,087CommonSOLE
76200L309RZLTREZOLUTE INC$8.5M1.20%903,442CommonSOLE
04335A105ARVNARVINAS INC$8.4M1.19%987,818CommonSOLE
28036F105EWTXEDGEWISE THERAPEUTICS INC$8.1M1.15%500,000CommonSOLE
03589W102ANNXANNEXON INC$7.9M1.12%2,600,000CommonSOLE
38341P102GOSSGOSSAMER BIO INC$7.2M1.01%2,725,000CommonSOLE
74366E102PTGXPROTAGONIST THERAPEUTICS INC$7.0M0.99%105,000CommonSOLE
48115J109DERMJOURNEY MEDICAL CORP$6.9M0.98%971,064CommonSOLE
M8694L137SLGLSOL GEL TECHNOLOGIES$6.0M0.84%204,835CommonSOLE
74365A309PLXPROTALIX BIOTHERAPEUTICS INC$5.7M0.81%2,580,556CommonSOLE
89455T109TMCITREACE MEDICAL CONCEPTS INC$4.7M0.67%702,245CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$4.7M0.66%100,000CommonSOLE
48576UAA4KPTI 3 10/15/25KARYOPHARM THERAPEUTICS INC$4.6M0.65%6,000,000CommonSOLE
55287L101MBXMBX BIOSCIENCES INC$4.4M0.63%253,000CommonSOLE
89532M101TRVITREVI THERAPEUTICS INC$3.6M0.50%390,000CommonSOLE
H0036K147ADCTADC Therapeutics SA$2.7M0.39%682,529CommonSOLE
022307102ALMSALUMIS INC$2.7M0.38%665,000CommonSOLE
12674W109CABACABALETTA BIO INC$1.9M0.27%808,882CommonSOLE
67577R102IRDOPUS GENETICS INC$1.8M0.26%1,100,000CommonSOLE
98985Y108ZYMEZYMEWORKS INC$1.7M0.24%100,000CommonSOLE
00773J202SYRESPYRE THERAPEUTICS INC$1.1M0.15%65,000CommonSOLE
766559702RIGLRIGEL PHARMACEUTICALS$1.1M0.15%37,787CommonSOLE
02074J501ACOGALPHA COGNITION INC$749,5740.11%115,142CommonSOLE
98943L107ZNTLZENTALIS PHARMACEUTICALS INC$477,9910.07%316,550CommonSOLE
713317105PEPGPEPGEN INC$346,5000.05%75,000CommonSOLE
451033708IBIOIBIO INC$310,4250.04%375,000CommonSOLE
00534B100ADGMADAGIO MED HLDGS INC$214,5080.03%110,571CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.